Phase II Study of Single Agent Obinutuzumab in Relapsed/Refractory Post-Transplant Lymphoproliferative Disorder (PTLD)
Latest Information Update: 24 Mar 2017
At a glance
- Drugs Obinutuzumab (Primary)
- Indications Post-transplant lymphoproliferative disorder
- Focus Therapeutic Use
- 24 Mar 2017 New trial record